Menarini Group and NewAmsterdam Pharma Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
RegulatoryapprovedUbeslo®Evlarco®Positive
AI Analysis
Summary
NewAmsterdam Pharma and Menarini Group received European Commission approval for Ubeslo® and Evlarco®, marking the first global regulatory approval of obicetrapib, a first-in-class therapy supported by Phase 3 trials demonstrating significant LDL-C reductions and favorable tolerability.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
European Commission approval for Ubeslo® (obicetrapib monotherapy) and Evlarco® (obicetrapib plus ezetimibe fixed-dose combination). First-in-class approval and first global regulatory approval of obicetrapib.
Importance:9/10
Sentiment:
0.95
regulatory approvalEuropean Commissionfirst-in-classLDL-C reductionPhase 3 dataBROADWAYBROOKLYNTANDEM
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on September 21, 2026 2:57 PM